CG Oncology (CGON) CEO nets 100,000 shares from option exercise

Rhea-AI Filing Summary

CG Oncology, Inc. Chief Executive Officer Arthur Kuan exercised employee stock options and increased his direct ownership. On March 4, 2026, he exercised options for 102,871 shares of common stock at $1.72 per share, receiving 100,000 shares after a net exercise in which the company withheld 2,871 shares and he paid the remaining exercise price in cash. A related disposition of 2,871 shares at $61.61 per share was recorded for payment of the exercise price or tax liability and, as noted, does not represent an open-market sale. Following these transactions, Kuan directly owned 136,151 shares of CG Oncology common stock.

Insider Trade Summary

102,871 shares exercised/converted

Mixed 3 txns

Insider Kuan Arthur

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	102,871	$0.00	--
Exercise	Common Stock	102,871	$1.72	$177K
Tax Withholding	Common Stock	2,871	$61.61	$177K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 64,612 shares (Direct); Common Stock — 139,022 shares (Direct)

Footnotes (1)

1. Represents a "net exercise" of outstanding stock options. The reporting person received 100,000 shares of common stock on net exercise of an option to purchase 102,871 shares of common stock. The Company withheld 2,871 shares of common stock underlying the option and the reporting person paid in cash the delta for payment in full of the aggregate exercise price. This transaction does not represent a sale by the reporting person. The stock option is currently vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kuan Arthur

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		102,871	A	$1.72	139,022	D
Common Stock	03/04/2026		F(1)		2,871	D	$61.61	136,151	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.72	03/04/2026		M			102,871	(2)	04/18/2031	Common Stock	102,871	$0	64,612	D

Explanation of Responses:

1. Represents a "net exercise" of outstanding stock options. The reporting person received 100,000 shares of common stock on net exercise of an option to purchase 102,871 shares of common stock. The Company withheld 2,871 shares of common stock underlying the option and the reporting person paid in cash the delta for payment in full of the aggregate exercise price. This transaction does not represent a sale by the reporting person.

2. The stock option is currently vested and exercisable.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Arthur Kuan	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CG Oncology (CGON) report for CEO Arthur Kuan?

CG Oncology reported that CEO Arthur Kuan exercised employee stock options for 102,871 shares on March 4, 2026. Through a net exercise, he received 100,000 shares of common stock and increased his direct holdings to 136,151 shares after related withholding transactions.

Did CG Oncology (CGON) CEO Arthur Kuan sell shares in the latest Form 4?

The filing shows no open-market sale by CEO Arthur Kuan. Instead, 2,871 shares were withheld and disposed of to cover the option exercise price or tax obligations, and the footnote explicitly states this transaction does not represent a sale by the reporting person.

How many CG Oncology (CGON) shares does CEO Arthur Kuan own after the Form 4 transactions?

After exercising options and related withholding, CEO Arthur Kuan directly owns 136,151 shares of CG Oncology common stock. This reflects the 100,000 net shares received from exercising 102,871 options, less 2,871 shares withheld to satisfy exercise price or tax-related obligations.

What was the exercise price on CG Oncology (CGON) CEO Arthur Kuan’s stock options?

The options exercised by CEO Arthur Kuan had an exercise price of $1.72 per share for 102,871 shares. The company processed this as a net exercise, with Kuan receiving 100,000 shares and paying part of the aggregate exercise price in cash alongside share withholding.

Why were 2,871 CG Oncology (CGON) shares disposed of in CEO Arthur Kuan’s Form 4?

The 2,871-share disposition was to pay the option exercise price or tax liability, recorded at $61.61 per share. According to the footnote, these shares were withheld by the company and the transaction does not represent a market sale by CEO Arthur Kuan.

Are the stock options in CG Oncology (CGON) CEO Arthur Kuan’s Form 4 vested and exercisable?

Yes. A footnote states that the stock option reported in the Form 4 is currently vested and exercisable. This means Arthur Kuan had the right to exercise the option when he completed the 102,871-share option exercise on March 4, 2026.